Oxycontin Patents Not Infringed, Drug Cos. Say At Trial

Law360, New York (September 23, 2013, 7:08 PM EDT) -- Impax Laboratories Inc. and other drug makers said Monday that generic versions of Purdue Pharma LP’s OxyContin do not infringe Purdue-held patents, opening a patent trial that could help end Purdue’s monopoly on some formulations of the popular painkiller.

Impax, Teva Pharmaceuticals USA Inc. and Sandoz Inc. said that their versions of a tamper-resistant type of OxyContin, known generically as oxycodone, do not infringe patents that Purdue licensed from a university.

“The techniques we used are the conventional standard techniques always used in this industry,” attorney...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.